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ABSTRACT
Extracellular vesicles (EVs) from a variety of stem cell sources are believed to harbour regenerative
capacity, which may be exploited for therapeutic purposes. Because of EV interaction with other
soluble secreted factors, EV activity may depend on the employed purification method, which
limits cross-study comparisons and therapeutic development. Raman spectroscopy (RS) is a quick
and easy method to assess EV purity and composition, giving in-depth biochemical overview on
EV preparation. Hereby, we show how this method can be used to characterise EVs isolated from
human liver stem cells and bone marrow mesenchymal stem/stromal cells by means of conven-
tional ultracentrifugation (UC) and size exclusion chromatography (SEC) protocols. The obtained
EV preparations were demonstrated to be characterised by different degrees of purity and
a specific Raman fingerprint that represents both the cell source and the isolation procedure
used. Moreover, RS provided useful hints to explore the factors underlying the functional diversity
of EV preparations from the same cell source, thus representing a valuable tool to assess EV
quality prior to functional assays or therapeutic application.
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Introduction
Extracellular vesicles (EVs) from adult stem cell are
believed to harbour regenerative capacity, which may
be exploited for therapeutic purposes. Their use as an
alternative to cell-based therapy in regenerative medi-
cine is currently under investigation in multiple clinical
scenarios spanning from renal failure [1,2] to myocar-
dial infarction [3,4] to musculoskeletal regeneration
[5,6] and neurological disorders [7]. The increasing
number of papers annually published on the regenera-
tive potential of EVs and the clinical trials started in the
field highlight the growing interest in their remarkable
translational opportunity as an off-the-shelf therapy. In
particular, EVs from human liver stem cells (HLSCs)
[8] and bone marrow mesenchymal stem/stromal cells
(MSCs) [2,9,10] have found promising application in
the regenerative medicine field. Both cell types express
markers typical of the mesenchymal lineage and are
able to undergo multiple in vitro differentiations. EVs
from HLSCs were demonstrated to contribute to liver
repair after hypoxia [8,11] and renal recovery after
acute kidney injury [1]. On the other hand, paracrine
factors of MSCs were shown to contain concomitant
regenerative and immunomodulatory functions that
act synergistically to accelerate the recovery of patients
[12,13].
Despite the handling and safety advantages of the
use of EVs in regenerative rehabilitation compared to
their cellular counterpart, the main hurdle for their
clinical application relies in the paucity of methods to
assess the reproducibility of current isolation methods
and in lack of quality and purity tests of EV suspen-
sions before use. Indeed, such difficulties have often
limited the comparison of results among laboratories
leading to conflicting conclusions regarding the actual
source of regenerative potential in the secretome of
stem cells, about the best purification method to be
used, as well as regarding their possible side effects in
clinical practice [14–16].
In the last decade, several isolation methods have
been described to isolate EVs [17], including the mostly
used differential ultracentrifugation (UC) and size
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exclusion chromatography (SEC), and new methods
are continuously being developed. EV purity differs
among isolation methods [18], and each method
enriches for different subpopulations of EVs, which
likely has direct implications for EV functionality
[19], data reproducibility and data (mis)interpretation.
The growing consciousness about the unpredictable
and unverifiable consequences of the isolation method
on EV purity and function [14] has motivated the ISEV
community to provide recommendations for the char-
acterisation of EV samples [20,21]. However, still no
consensus has been found about the most translational
and reproducible method for EV production among
those working in the regenerative medicine field, limit-
ing therapeutic development.
The identification of a quick and easy method to
assess EV purity and composition is crucial to ensure
batch reproducibility. Simple measurements on particle
counts and protein concentration may give a quick first
overview, but they do not provide information on
particle biochemical composition and cargo. Likely,
such information is required for Food and Drug
Administration (FDA) approval of EV-based therapeu-
tics [21].
Raman spectroscopy (RS) is an inelastic light-
scattering technique that detects the molecule-specific
vibrations of a sample illuminated by a monochromatic
laser. Each molecular species has its own unique set of
molecular vibrations that, without the use of any label,
comprise the series of peaks or bands that determine
the Raman spectrum (fingerprint). RS has already been
applied to EV characterisation with both diagnostic
and basic science purposes [22–24]. In particular, sev-
eral studies reported the use of RS for single vesicle
analysis from cell culture supernatants [22,23] taking
advantage of optical tweezers to trap vesicles and to
obtain single EV fingerprinting. However, the single
vesicle approach was demonstrated to be time-
consuming and inefficient because of the weak
Raman signals that often need the enhancement
mediated by nanostructured substrates or nanoparticles
for a more effective analysis [25–27].
Starting from our previous data on RS of EVs from
MSCs [28], we provide herein a proof of concept for
the use of the bulk characterisation by RS as suitable
method to give quick in-depth information on EV
purity and composition. We evaluated its ability to
detect differences in stem cell–derived EV content in
terms of protein-to-lipid and nucleic acids-to-lipid
ratio. In parallel, we investigated the effect of the pur-
ification method on in vitro pro-proliferative activity of
HLSC- and MSC-derived EVs comparing conventional
UC protocols with a previously described SEC-based
protocol [29]. Our results demonstrate that Raman
analysis can reveal differences in EV preparations
resulting from the employed isolation procedure,
using a 5 min acquisition protocol. This may help to
quickly assess EV purity and composition and predict
their functionality.
Materials and methods
All of the relevant experimental data have been sub-
mitted to the EV-TRACK knowledgebase (EV-TRACK
ID: EV180050) [30].
Cell culture and EV isolation
HLSCs were prepared from human cryopreserved nor-
mal adult hepatocytes purchased from Lonza (Basel,
Switzerland) as described elsewhere [31]. Bone mar-
row-derived MSCs were also obtained from Lonza,
and HK-2 cells were purchased from ATCC. All cells
were cultured in their corresponding medium (HLSCs:
Alpha MEM with L-glutamine (Lonza), 25% (v/v)
Endothelial basal medium supplemented with EGM-
MV SingleQuots (Lonza), 10% (v/v) foetal bovine
serum (FBS) and 100 U/mL penicillin/streptomycin
(Gibco), MSCs: MSCBM hMSC basal medium
(Lonza) with MSCGM hMSC SingleQuot Kit (Lonza),
HK-2: DMEM high glucose (Euroclone), 1% (v/v)
L-glutamine, 10% (v/v) FBS and 100 U/mL penicillin/
streptomycin) at 37°C and 5% CO2. For EV produc-
tion, stem cells were grown to 80–90% confluency,
washed once with PBS and cultured for 16 h in EV
production medium (RPMI 1640 (Euroclone) with
100 U/mL penicillin/streptomycin (Gibco), ± 0.1 mL
medium/cm2). This medium contained a negligible
amount of particles when analysed by Nanoparticle
Tracking Analysis (see below). Conditioned medium
was harvested from cells and centrifuged for 5 min at
300 g at 4°C. The supernatant was centrifuged for
15 min at 2000 g at 4°C and the resulting supernatant
was filtered through 0.8 μm syringe filters for the
removal of cells and debris. Conditioned medium was
then stored at −80°C or processed for EV purification
immediately. For EV purification, conditioned medium
was equally distributed over tested purification meth-
ods. For the 1x UC protocol, conditioned medium was
centrifuged at 100000 g for 70 min at 4°C in a type 70
Ti rotor (Beckman Coulter). Pellets were re-suspended
and pooled in 150 μL of PBS. For the 2xUC protocol,
pellets were re-suspended and pooled in 24 mL of PBS
instead, and centrifuged again at 100000 g for 70 min
at 4°C. Pellets were re-suspended in 150 μL of PBS. For
the SEC protocol, conditioned medium was
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concentrated to 1–2 mL using 15 mL Amicon ultrafil-
tration units with 100 kD molecular weight cut-off
(MWCO) at 2000 g at 4°C. A HiPrep 16/60 Sephacryl
S-400 HR gel filtration column was connected to an
ÄKTApurifier chromatography system, and equili-
brated with 150 mL of PBS at room temperature.
Concentrated medium was injected using a 2 mL
loop, and EVs were eluted at 0.7 mL/min with PBS,
while 5 mL fractions were collected. EV fractions
(35–55 mL) and non-EV fractions (65–145 mL) were
collected, filtered through 0.45 μm syringe filters, and
concentrated using 15 mL Amicon ultrafiltration units
with 100 kD and 30 kD MWCO, respectively, to a final
volume of ≈ 200 μL. After EV purification, EVs were
re-suspended thoroughly using 1 mL syringes with 26G
needles, and centrifuged for 10 min at 5000 g at 4°C to
remove any large aggregates, which interfere with
quantitation. EV and non-EV preparations were stored
at 4°C for maximally 5 days before use in in vitro
assays. The remaining samples were store at −80°C
after addition of 1% DMSO.
EV quantification and size measurement
EV concentration was quantified using Nanoparticle
Tracking Analysis (NTA) using a Nanosight LM10
system or a Nanosight NS300 system with syringe
pump. For both systems, EVs were diluted to appro-
priate dilutions using 0.1 μm filtered PBS, and five
movies of 30 s were recorded at camera level 15,
while a flow of 30 was applied (NS300 system only).
Movies were analysed at detection threshold 6 using
NTA 3.2 software, and PBS background (if any) was
subtracted for concentration calculations. Protein con-
centration of samples was determined using
a MicroBCA Protein Assay kit (Pierce) according to
the manufacturer’s instructions using a calibration
curve of bovine serum albumin (BSA).
SDS-PAGE and western blotting
To prepare cell lysates, cells grown in culture flasks were
washed with PBS and lysed in 1x RIPA buffer (1% v/v NP-
40, 0.5% w/v octyl glucoside, 6.4 mM EDTA, 0.1% w/v
sodium dodecyl sulphate (SDS) in PBS) with protease
inhibitor cocktail (Sigma-Aldrich, P8340) on ice for
20 min. Lysates were collected with cell scrapers and cen-
trifuged for 10min at 10000 g and 4°C to remove insoluble
debris. Protein concentrations were determined using
a MicroBCA Protein Assay kit as described above. EVs in
PBS were mixed with 0.1 volume of 10X RIPA buffer and
lysed on ice for 10 min. Subsequently, samples were mixed
with sample buffer (final concentration: 10% v/v glycerol,
62mMTris HCl, 2% v/v SDS). For detection of all proteins
except CD63 and flottilin-1, samples were reduced by
addition of 8.3 mM dithiothreitol (DTT). Subsequently,
samples were heated to 95°C for 10 min and electrophor-
esed over 4–12% Bis-Tris polyacrylamide gels (Thermo
Fisher Scientific). Proteins were electrotransferred to
Immobilon-FL polyvinylidene difluoride (PVDF) mem-
branes (Merck Millipore, Amsterdam, The Netherlands)
and blocked in 50% v/v Odyssey blocking buffer (LI-COR
Biosciences, Leusden, The Netherlands) in Tris-buffered
saline (TBS). Antibody incubations were performed in
50% v/v Odyssey blocking buffer (LI-COR Biosciences,
Leusden, The Netherlands) in Tris-buffered saline with
0.1% Tween20 (TBS-T). Primary antibodies and dilutions
included mouse-anti-Alix (Abcam, clone 3A9, 1:1000),
rabbit anti-Calnexin (Origene, cat. no. TA336279,
1:1000), rabbit anti-Calreticulin (Proteintech, cat. no.
10,292–1-AP, 1:1000), mouse anti-CD63 (Abcam, clone
MEM-259, 1:1000), rabbit anti-flotillin-1 (Merck
Millipore, clone EPR6041, 1:1000), rabbit anti-TSG101
(Abcam, cat. no. ab30871, 1:1000), mouse anti-β-actin
(Cell Signalling Technology, clone 8H10D10, 1:1000), rab-
bit anti-CD9 (Abcam, clone EPR2949, 1:1000), mouse
anti-CD81 (Santa Cruz Biotechnology, clone B-11,
1:500). Secondary antibodies were applied at a 1:7500 dilu-
tion and included Alexa Fluor 680-conjugated anti-rabbit
or anti-mouse antibodies (Thermo Fisher Scientific, cat.
no. A-21076 and A-21057, respectively) and IRDye
800 CW anti-mouse or anti-rabbit antibodies (LI-COR
Biosciences, cat. no. 926–32212 and 926–32211, respec-
tively). Blots were visualised using an Odyssey Infrared
Imager (LI-COR) at 700 and 800 nm.
Electron microscopy
Copper carbon-coated formvar grids were incubated for
20 min on 7 µL of EV solutions at room temperature in
a humidified chamber. Grids were washed twice with PBS
and were subsequently incubated on 1% glutaraldehyde in
PBS for 15 min at room temperature. Grids were washed
eight times with Milli-Q water (Merck Millipore) and
stained with uranyl-oxalate (pH 7) for 7.5 min.
Subsequently, grids were incubated for 5 min on methyl
cellulose uranyl-acetate (pH 4) on a cold metal plate, after
which embedding solution was carefully drained using
filter paper. Grids were imaged using a Tecnai T12 trans-
mission electron microscope (FEI, Eindhoven, The
Netherlands).
EV purity assay
The purity of the EV suspensions was determined by
means of two different methods. Firstly, a purity score
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was obtained by calculating the ratio between the num-
ber of particles and the total protein content measured
by NTA and MicroBCA assay, respectively, on the
same sample [18]. Secondly, purity was determined
through a previously published colorimetric nanoplas-
monic assay [32]. Briefly, EVs from 1x UC, 2x UC and
SEC were incubated with gold spherical nanoparticles
(6 nM) for 30 min. A UV-Vis Spectrophotometer
allowed to measure the ratio between the absorption
peak at 520 and 650 nm defined as the aggregation
index (AI). The AI represents the quantification of the
nanoparticles that remain dispersed in the solution and
thus keep the 520 nm absorption peak and the aggre-
gated ones that, once in clusters, shift their absorption
peak at 650 nm. Gold nanoparticles remain dispersed
in solution if they become coated with proteins,
whereas they tend to aggregate when in contact with
the vesicle membrane surface, thus being an indicator
of the presence of soluble contaminant proteins. The
AIs were normalised for the protein concentration and
are indicative of the purity level of the sample.
Raman spectroscopy
EVs were analysed by means of Raman microspectro-
scopy (LabRAM Aramis, Horiba Jobin Yvon S.A.S,
Lille, France) following a previously described protocol
[28]. Briefly, 5–10 µl drops of EV suspension were
deposited on a calcium fluoride slide. All of the mea-
surements were performed on the air-dried drop with
50x objective, 1800 grooves/mm diffraction grating,
400 µm entrance slit, and confocal mode (300 µm pin-
hole) in the spectral ranges 600–1800 cm−1 and
2600–3200 cm−1. The Raman shift was calibrated auto-
matically using LabSpec 6 software (Horiba) using
zero-order line and Si line of a Si reference sample.
Taking advantage of Labspec6, baseline correction
(sixth order polynomial curve), unit vector normalisa-
tion and post-acquisition calibration were carried out
on normalised spectra, in order to compensate for
autofluorescence, background interference and possible
thermal drifts.
Raman spectra were also obtained for purified cho-
lesterol (Chol), sphingomyelin (SM) and phosphatidyl-
choline, (16:0/22:6; PC) purchased from Avanti Polar
Lipids (Alabaster, AL, USA), and from SNAP-25
(Thermo Fisher Scientific, Waltham, MA, USA) and
RNA (miRNA sequence of 21 bp; ATDBio Ltd,
Southampton, UK) with the same acquisition para-
meters in order to compare peaks from reference mole-
cules with those from EV samples.
Raman spectra from EVs were then used to measure
the spectroscopic protein-to-lipid (P/L) and nucleic
acid-to-lipid (NA/L) ratio, adapting the protocol vali-
dated by Mihály for IR spectroscopy [33]. Since pro-
teins, lipids and nucleic acids show distinctive
absorption bands by both IR and Raman spectroscopy,
we used the Raman spectrum to estimate the P/L and
NA/L ratio by dividing the relative intensity of amide
I protein band (1600–1690 cm−1) and nucleic acid
band (720–800 cm−1) by the lipid-related band
(2750–3040 cm−1), respectively [34,35].
Proximal tubular cell proliferation assays
Human proximal tubular cells (HK-2 cells) were
seeded at 200–800 cells/well in a 96-well plate and
incubated at 37°C. After 24 h, cells were washed with
PBS and medium was replaced for HK-2 starvation
medium (DMEM high glucose (Euroclone), 1% (v/v)
L-glutamine, 100 U/mL penicillin/streptomycin, 1x
ITS liquid medium supplement (Sigma-Aldrich),
10 µg/mL hydrocortisone and 25 ng/mL epidermal
growth factor (EGF). EVs or PBS were added in tripli-
cates, and cells were incubated for 72 h at 37°C. EVs
were added at a dose of 10E4 or 10E5 particles/cell, or
concentrated non-EV fractions of SEC purification of
HLSC-derived EVs at a similar volume as EVs or 10-
fold serial dilutions thereof. As a positive control for
proliferation, cells were incubated with normal growth
medium instead of starvation medium. Sixteen hours
before the end of the incubation, BrdU labelling
reagent (Roche) was added at a concentration of
10 μM. After 16 h, BrdU cell proliferation ELISA
(Roche) was performed and analysed according to the
manufacturer’s instructions.
Statistical analysis
RS data were analysed by descriptive and multivariate
statistical analysis by means of Origin2018 (OriginLab,
Northampton, MA, USA). Principal component analy-
sis (PCA) of the normalised spectra provided principal
components (PCs) that represent differences in the
spectra of EVs. Linear discriminant analysis (LDA)
was used to discriminate and classify the data. The
PCA-LDA attributes to each spectrum of (n-1) canoni-
cal variables (n = number of the considered groups)
that allow to construct a classifier for the EV groups
and to potentially classify unknown spectra. The first
two canonical functions are those that reflect the most
variance in discriminant model. The smallest number
of PC scores was selected for the LDA to prevent data
over-fitting. To test the sensitivity, specificity and accu-
racy of the LDA model, leave-one-out cross-validation
was used. One-way ANOVA was performed on PC
4 A. GUALERZI ET AL.
scores and on proliferation assay results to verify the
significance of group differences.
Results
Characterisation of EVs
EVs from HLSC and MSC in vitro cultures were suc-
cessfully purified using 1x UC, 2x UC and SEC isola-
tion protocols and characterised following the ISEV
guidelines (MISEV2018) [36]. NTA analysis showed
that particle size distribution did not significantly differ
between the three isolation methods, although gener-
ally UC-isolated EVs tended to be slightly smaller than
those from SEC (mean size 1x UC EVs: 184 ± 33 nm
(HLSC) versus 212 ± 34 nm (MSC); 2x UC EVs:
189 ± 27 nm (HLSC) versus 204 ± 42 nm (MSC);
SEC EVs: 228 ± 50 nm (HLSC) versus 247 ± 68 nm
(MSC), data from at least five isolations, Figure 1(a)).
Transmission electron microscopy (TEM) analysis
(Figure 1(b)) corroborated this data, and showed EVs
with similar, “cup-shaped” morphology in all prepara-
tions. Furthermore, EVs obtained with all isolation
protocols showed a similar expression of canonical
EV markers CD81 and CD63 by western blot analysis,
but CD9 and β-actin were virtually absent (Figure 1
(c)). Nuclear and endoplasmic reticulum proteins cal-
nexin and calreticulin, respectively, were also absent in
all EV preparations. HLSC EVs were enriched in Alix
and TSG101, but these proteins could hardly be
detected in MSC EVs. On the contrary, expression of
flotillin-1 appeared to be more prominent in MSC EVs
compared to HLSC EVs.
Despite these similar protein expression profiles
among EVs from the same cell type but isolated using
different isolation protocols, EV preparations differed
in their purity expressed as the ratio of particles per
microgram of protein, with significantly increased pur-
ity obtained with the 2x UC and SEC protocols com-
pared to 1x UC (Figure 1(d); ANOVA p < 0.05 for 1x
UC vs 2x UC; p < 0.01 for 1x UC vs SEC). These data
were confirmed by a nanoparticle-based assay that
exploits the property of a colloidal solution of gold
nanoparticles to shift from red to blue proportionally
with the purity grade of the analysed EV preparation
[32,37]. Consistently with observations from other
authors [37], the nanoplasmonic assay confirmed that
both UC samples contain more exogenous contami-
nants compared to SEC samples, and thus
a significantly lower normalised AI, that is a measure
of soluble contaminants coating gold nanoparticles and
preventing their aggregation on the membrane surface
of EVs (Figure 1(e); ANOVA p < 0.01 for 1x UC and
2x UC vs SEC).
Raman analysis of EVs
Starting from our previously published protocol [28], we
performed a bulk characterisation of EV suspensions
from HLSC and MSC in order to evaluate the overall
biochemical features of the EV preparations. Spectra
were acquired on air-dried drops of EV suspensions,
from both cell types, in the spectral range 600–1800
cm−1 and 2600–3200 cm−1. The intensity and signal-
to-noise ratio of the spectra revealed a progressive
increase going from 1x UC to 2x UC and SEC in both
HLSC- and MSC-derived EVs (Figure 2(a) and (b);
Supplementary Figure 1 shows average spectra and
their corresponding standard deviations). In particular,
the average spectra obtained for SEC EVs were charac-
terised by more defined peaks and less intense contribu-
tion of fluorescence and background noise. Nonetheless,
the same post-processing procedure (baseline subtrac-
tion and unit vector normalisation) was applied to all
raw data in order to compare spectra to reference mole-
cules and to proceed with statistical analysis. The 2x UC
and SEC spectra of EVs from both cell types showed
characteristic Raman bands of proteins (Amide I 1600–
1690 cm−1; Amide III 1200–1300 cm−1), lipids
(2700–3200 cm−1) and nucleic acids (720–820 cm−1).
In particular, beside the bands related to CH and CH2
groups (respectively, centred at 1450 cm−1 and
2940 cm−1) of both proteins and lipids, the main peaks
which appeared in all samples were located at 679 cm−1
(nucleic acids), 710–713 cm−1(phospholipids),
928–940 cm−1 (proteins; Pro and Hydroxy-Pro),
1003 cm−1 (Phe); 1055 and 1130 cm−1 (lipids and pro-
teins). Although attenuated in 1x UC samples, bands
and peaks specifically associated with nucleic acids
(679 cm−1; 788 cm−1; 1115.9 cm−1; 1337 cm−1) were
present in all samples. Further peak assignment is
reported in Supplementary Table 1. As a reference, in
Figure 2(c), the Raman spectra of reference molecules of
single-stranded RNA, protein (SNAP25 was selected as
a reference protein; it is a membrane-bound protein of
the SNARE family, known to mediate fusion of cyto-
plasmic vesicles) and of typical membrane lipids (Chol,
SM and PC) are shown. All the obtained Raman data
from EV samples were considered for multivariate PCA-
LDA analysis in order to verify the ability of RS to
distinguish among EVs isolated by means of the three
considered isolation procedures, 1x UC, 2x UC and SEC
(Figure 3). Spectra obtained from non-EV fractions
obtained during SEC purification were also included in
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Figure 1. Characterisation of EV samples obtained with 1x UC, 2x UC and SEC protocols. a: Representative size distribution obtained
using NTA on HLSC and MSC EV samples obtained with 1x UC, 2x UC and SEC protocols. b: Representative transmission electron microscopy
(TEM) pictures of HLSC and MSC EVs obtained with all three isolation protocols. Scale bars represent 100 nm. c: Western blots of cell and EV
lysates fromHLSCs andMSCs. For cell lysates, 10 µg (HLSCs) and 5 µg (MSCs) of protein was loaded. EV lanes contained 2E10 particles (HLSCs)
or 0.8E10 particles (MSCs). d: EV purity expressed as the ratio of particles and µg of protein, calculated by NTA and colorimetric microBCA
protein assay respectively. e: Aggregation index (AI) of each sample obtained after the nanoplasmonic assay and normalised for the protein
concentration as calculated by micro BCA protein assay. * indicates p < 0.05, ** p < 0.01 after one-way ANOVA with Tukey post-hoc test.
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the analysis and used as internal control. In
Supplementary Figure 2, the loadings of the first three
PCs used to build the classification model are reported.
The scatter plot in Figure 3(a) graphically represents the
PCA-LDA results on EV and non-EV spectra, showing
that the proposed procedure was capable to distinguish
between EV samples and non-EV samples. Each dot is
defined by the scores attributed by the multivariate
analysis PCA-LDA to each spectrum from HLSC- and
MSC-derived EVs and non-EV fractions, i.e. canonical
variables 1 and 2 that reflect the most variance in the
discriminant model and allow the classification of spec-
tra. Significant differences in the canonical variable 1 for
EV and non-EV samples and between the different
isolation methods were observed (Figure 3(c)). After
leave-one-out cross-validation, the classification model
was demonstrated to reach a good sensitivity and speci-
ficity with an overall accuracy in distinguishing EVs
from non-EVs of 97%, when spectra of HLSC- and
MSC-derived EVs are considered as a whole. We then
verified the ability of the method to distinguish between
HLSC- and MSC-derived EVs isolated by 1x UC, 2x UC
and SEC. The PCA-LDA analysis was, therefore,
repeated considering only the EV spectra (Figure 3(b)).
The mean value of canonical variable 1 obtained for
HLSC- and MSC-derived EVs was demonstrated to be
significantly different between 2x UC (p < 0.01) and SEC
(p < 0.001) samples, but no significant difference was
obtained between 1x UC samples from the two cell types
(Figure 3(d)). Our results demonstrated that the purity
of EV preparations (as assessed by purity and nanoplas-
monic assays) correlated with the specificity of the
Raman fingerprint (specificity of 99.2% for HLSC-SEC-
derived EVs and 94.9% for MSC-SEC-derived EVs ver-
sus 1x and 2x UC samples). Hence, the purer the EVs,
the more accurate RS could distinguish the cell source.
Spectroscopic protein-to-lipid and nucleic acid-to-
lipid ratio
In order to deepen the biochemical constituents that
account for the spectral differences among the isola-
tion procedures in both HLSC- and MSC-derived
EVs, the spectroscopic P/L was calculated for all
samples. P/L and NA/L were calculated for all EV-
samples by dividing the relative intensity of amide
I protein band (1600–1690 cm−1) and nucleic acid
band (720–800 cm−1) by the lipid-related band
(2750–3040 cm−1), respectively. As shown in Figure
4(a), the P/L value in the samples varied depending
on the isolation protocols. Specifically, the P/L
obtained for HLSC-derived EV after 1x UC was sig-
nificantly higher (p < 0.001) compared to 2x UC and
SEC isolated EVs from the same cell type. Significant
differences were also observed between the P/L of 2x
Figure 2. Raman spectra of EV samples and reference molecules. a-b: Mean Raman spectra obtained on air-dried drop of EV
samples isolated by 1x UC, 2x UC and SEC protocols from HLSC (a) and MSC (b) supernatants. All spectra were baseline corrected,
aligned and normalised before averaging. c: Representative Raman spectra of reference molecules: cholesterol (Chol), sphingomye-
lin (SM), phosphatidylcholine (PC), SNAP 25 recombinant protein and single stranded RNA. All spectra were obtained with 532 nm
laser line and 30 s of exposure for 2 accumulations.
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UC and SEC isolated EVs from MSCs, but not
between 1x UC and 2x UC EVs from MSCs.
The same spectroscopic measurement was also per-
formed to verify the NA/L, in order to assess if differ-
ences in the nucleic acid load of EVs were detectable
between EV preparations with different purity degrees.
As shown in Figure 4(b), no difference was detected in
the NA load among MSC-derived EVs, whereas
a significant difference in NA/L was found between
HLSC-derived EVs, in particular between 1x UC sam-
ples and the purer 2x UC and SEC samples.
Collectively, these data demonstrate that 1x UC and
2x UC protocols result in the co-isolation of more non-
EV protein contaminants than the SEC procedure.
Furthermore, the Raman data suggested that the
HLSC secretome is richer than the MSC-derived secre-
tome in soluble protein factors that can be co-isolated
with EVs when undergoing a1x UC isolation protocol.
On the contrary, the reported differences in the NA/L
do not show a direct correlation with the purity degree
of EV samples.
Proliferation assay
To assess differences in the ability of EVs isolated by
means of different purification methods to affect
proliferation, the proliferative effects of MSC- and
HLSC-derived EVs were tested on in vitro cultures
Figure 3. Multivariate statistical analysis of Raman spectra. PCA-LDA analysis performed on all spectra obtained on EV and non-
EV samples from HLSC and MSC (n ≥ 25 per sample). a,b: Scatter plots representing the values obtained for the Canonical Variable 1
and Canonical Variable 2 after LDA. In the classification model shown in (a), spectra from EVs were grouped based on their isolation
method and non-EV spectra were analysed as an internal control. In (b), spectra were grouped based on both isolation method and
cell source. In both analyses, the first 20 PC scores calculated by means of PCA were used for the LDA. Each dot represents a single
spectrum. c,d: Box plots representing the Canonical Variable 1 obtained for every considered group of samples after the
corresponding LDA analysis. In (c), the ability of RS to distinguish between EV and non-EV samples and between EV samples
isolated by means of different protocols was verified. In (d), the Canonical Variable 1 was considered to evaluate the ability of RS to
distinguish between HLSC- and MSC-derived EVs, isolated by different procedures. * indicates p < 0.05, ** p < 0.01, *** p < 0.001
after one-way ANOVA with Tukey post-hoc test.
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of the proximal tubular cells. After 72 h of treatment
with equal numbers of particles as determined by
NTA, a pro-proliferative effect of EVs was observed
which depended on the purification method used. In
particular, EVs isolated using the 1x UC protocol
from both MSC- and HLSC-derived conditioned
medium dose-dependently affected the proliferation
of HK-2 cells (Figure 5(a, b)). Interestingly, MSC-
derived EVs isolated using the 2x UC and SEC pro-
tocols did not alter the proliferative rate of HK-2
cells compared with untreated cells. On the contrary,
HLSC-derived EVs isolated by means of the 2x UC
protocol-induced cell proliferation (p < 0.01), but not
their corresponding SEC-isolated EVs. In general,
EVs from both stem cell sources promoted prolifera-
tion of proximal tubular cells, but these effects
decreased with increasing EV purity. Notably, con-
centrated HLSC-derived non-EV fractions showed
strong pro-proliferative effects on proximal tubular
cells (data not shown).
Discussion
Secretome-based approaches are increasingly being
applied in regenerative medicine. In particular, EVs
released by stem cells have been demonstrated to induce
regenerative effects via horizontal transfer of proteins,
nucleic acids and bioactive lipids to the target cells.
Unfortunately, the cellular origin and the isolationmethod
of EVs can affect EV performance. In addition, the com-
plexity of EV preparations in terms of subpopulation
enrichment and contamination with other secretome or
culture medium-derived products [38,39] can represent an
impediment for regulatory approval of regenerative stem
cell-derived therapeutics. A cost-effective, robust and
straightforward method for the quality and purity control
of EVs is thus urgently needed.
We demonstrated herein that RS can be used to
characterise stem cell-derived vesicles isolated by means
of different protocols and with different purity degrees,
obtaining a specific Raman fingerprint that accounts for
Figure 4. Spectroscopic protein-to-lipid and nucleic acid-to-lipid ratios. Box plots showing the spectroscopic protein-to-lipid
ratio (P/L) in (a) and nucleic acid-to-lipid ratio (NA/L) in (b). Differences in the P/L and NA/L values obtained for HLSC- and MSC-
derived EVs isolated by different methods were compared. ** indicates p < 0.01, *** p < 0.001 after one-way ANOVA with Tukey
post-hoc test.
Figure 5. Proliferation assay. Effect of HLSC (a) and MSC (b) derived EVs at doses of 10E4 or 10E5 particles/cell on HK-2 cells
cultured under serum-free conditions. After 72 h, proliferation was determined using a BrdU cell proliferation ELISA. Proliferation of
treated samples was expressed as a percentage of the proliferation of untreated cells. * indicates p < 0.05, ** p < 0.01, *** p < 0.001
after one-way ANOVA with Dunnett’s post hoc test.
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both the cell source and the isolation procedure used. Our
data suggest that the Raman fingerprint of the EVs
obtained by 1x UC protocol is strongly influenced by the
presence of co-isolated soluble factors that seem to mask
the source-related biochemical features of EVs. In our
experimental setting, once the isolation procedure allowed
the preparation of a pure EV sample, RS revealed its cell-
specific spectroscopic features. Our findings support the
use of RS for the label-free bulk characterisation of stem
cell-derived EVs before their application in vitro and
in vivo to verify the reproducibility of the isolation and
the presence of co-isolated soluble factors. Hence, it may be
used for manufacturing and quality control in the pre-
clinical phase of EV-based therapeutics.
Besides providing an overall biochemical characterisa-
tion of the sample, the Raman spectrum was also demon-
strated to give information about the purity of EVs. For
this, we adapted the IR-based spectroscopic method pro-
posed and validated by Mihály and colleagues [33] and
verified the ability of the method to reflect differences
among EV subpopulations. As previously suggested, the
spectroscopic P/L data can become an additional para-
meter in the routine quality control of EV preparations
and can help exploring the observed differences in EV
preparations. Although the investigation of the mechan-
isms underneath the differences in the functionality of
stem-cell derived secretome and EVs goes beyond the
scope of the present work, our findings support the
hypothesis that such differences in the biological effect of
the secretome of HLSCs and MSCs can be both related to
EV and non-EV components, in accordance with pre-
viously reported data demonstrating that not all proteins
involved in the regenerative functions of stem cells are
released as vesicular cargos [40,41]. As a matter of fact,
the 1x UC of HLSC-derived EVs were demonstrated to
have a higher P/L ratio compared to purer 2x UC and SEC
samples that might be explained by contaminant protein
components that arewashed out and removed from the EV
preparation when the 2x UC and SEC protocols are
applied. 1x UC samples were also demonstrated to be
more effective in inducing the proliferation of proximal
tubular cells, compared to the other EV preparations in
a dose-dependent manner suggesting that the pro-
proliferative effect of HLSC-secretome might derive from
the synergistic action of EVs and soluble factors. However,
it should be noted that, although we did not observe a loss
of EV integrity in 2x UC and SEC protocols compared to
the 1x UC protocol by TEM analysis, changes in EV
integrity could partially contribute to the loss of EV activity
in preparations of higher purity. Our data are in agreement
with previously reported data that demonstrated how con-
ditioned medium can induce kidney regeneration after
acute injury [1]. EV-depleted medium reduced but did
not abrogate the regenerative effect, even though the latter
was not able to induce pro-proliferative effects. Similarly,
the low dose of 1x UC MSC-derived EVs was able to
induce proliferation in proximal tubular cells, but MSC-
derived EV preparations showed lessmarked differences in
the P/L value when comparing the three isolation proce-
dures making us speculate that EVs from MSC are part of
a less soluble protein-enriched secretome compared to the
HLSC one.
In parallel, the spectroscopic NA/L was calculated
following the same protocol, but no significant differ-
ence was noted among the considered EV samples. In
this regard, we have to mention that this result could
be due to the complexity of EV sample that limit the
sensitivity of the Raman spectrum in detecting nucleic
acids when other molecular entities are more abundant
and can partially mask their signal.
Taken as a whole, our data showed the ability of
RS to perform a bulk biochemical characterisation of
EV preparations and suggested the Raman approach
as a rapid (≤ 5 min), label-free method for the
investigation of stem cell-derived secretome.
Compared to the single vesicle approach that require
even more sophisticated instruments and laborious
protocols, the proposed procedure for RS can be
considered an economical and fast alternative for
other-omic approaches, such as differential proteo-
mics [40], which already proved to be a successful
tool to characterise the secretome of stem cells. It is
worth noting that, beside the above-described advan-
tages, the proposed method has some limitations.
Some compounds may mask the EV-fingerprint,
thereby limiting proper Raman fingerprinting. For
example, in our hands, Raman analysis is not suita-
ble for EV preparations obtained by either commer-
cial precipitation kits containing PEG or other
polymers, nor density gradient purification mediated
by sucrose, iodixanol or similar moieties that usually
remain in the preparation even after the introduction
of a washing step.
We hypothesise that Raman analysis can be intro-
duced in the pipeline of stem cell-derived EVs produc-
tion as quality control and as a tool to identify the best
EV-isolation procedure for a specific cell type. Our
Raman data should be considered integrative to exist-
ing protein-based databases (e.g. Vesiclepedia,
Exocarta) and, if further validated, could lead to the
generation of online databases that can merge Raman
data of EVs from various sources with the existing
protein and RNA databases generated by the EV com-
munity to foster transparency and reproducibility of
data and help comparison and standardisation of
methods.
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